GEMOX方案一线治疗老年晚期胆囊癌临床观察  

Clinical observation of GEMOX first -line treatment for elderly patients with advanced gall bladder cancer

作　　者：魏艳红[1] 杨洁[1] 张尚暖[1] 祝倩倩[1] 张君莹[1] 韩正祥[1] 

机构地区：[1]徐州医学院附属医院肿瘤科,江苏徐州221002

出　　处：《徐州医学院学报》2013年第9期580-582,共3页Acta Academiae Medicinae Xuzhou

基　　金：江苏省卫生厅医学科技发展基金会临床肿瘤学科研课题（P200942）;徐州医学院课题（08KJ53）

摘　　要：目的 评价吉西他滨（GEM）联合奥沙利铂（L-OHP）一线治疗晚期胆囊癌的近期疗效和毒副反应.方法 晚期胆囊癌21例.GEM 800 mg/m^2,第1、8天静脉给药;L-OHP 85 mg/m^2,第1天静脉给药;21天为1个疗程.2个疗程后评价患者的疗效、KPS评分、临床受益反应（CBR）、毒副反应等.结果 完全缓解（CR）0例,部分缓解（PR）5例,稳定（SD）7例,进展（PD）9例,总有效率（CR＋PR）为23.8%,CBR为57.1%.化疗前后KPS评分差异无统计学意义（P＞0.05）.毒副反应主要为骨髓抑制（11例）、胃肠道反应（8例）、神经病变（3例）.结论 GEM联合L-OHP一线治疗晚期胆囊癌近期疗效较好,毒性反应较轻,老年患者依从性好.Objective To evaluate the efficacy and toxicity of combination chemotherapy with gemcitabine and ox- aliplatin （GEMOX） as first - line therapy （GEMOX） for patients with advanced gall bladder cancer. Methods 36 eld- erly patients with advanced gall bladder cancer received gemcitabine 800 mg/m^2 （ day 1 and 8 ） and oxaliplatin 85 mg/m2 （ day 1 ） , every 3 weeks and at least 2 cycles. The evaluation was performed after the chemotherapy for 2 cycles. 36 patients were evaluable for efficacy, physical fitness score （KPS） , clinical benefit response （CBR） ,and toxicity, etc. Resuits No complete remission （CR） was observed. Partial remission （PR） was observed in 5 cases, stable disease （SD） in 7 cases and progressive disease （PD） in 9 cases. The objective response rate （defined as CR ＋ PR） was 23.8% （5/21 ） and C BR was 57.1%. KPS score difference was not statistically significant （P 〉 0.05 ） before and after chemotherapy. The main adverse effects were ： myelosuppression （ 11 cases）, gastrointestinal reactions （ 8 cases） and neurosensory toxicity （3 cases）. Conclusion Oxaliplatin plus gemeitabine first - line therapy for the treatment of ad- vanced biliary tract carcinoma has good short -term effect with mild adverse effects and are well tolerated in elderly pa- tients.

关 键 词：晚期胆囊癌 吉西他滨 奥沙利铂 化学治疗 

分 类 号：R735.8[医药卫生—肿瘤]